SILENCE THERAP. SP.ADR/1 (XRP2) — Financial Flexibility Index
SILENCE THERAP. SP.ADR/1 (XRP2) has a Financial Flexibility Index of -0.25x as of December 2025. Free cash flow of €-17.29 Million (operating CF €-17.29 Million minus capex €0.00) represents 0% of total liabilities (€69.14 Million). Check SILENCE THERAP. SP.ADR/1 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
SILENCE THERAP. SP.ADR/1 Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for SILENCE THERAP. SP.ADR/1 across 5 annual periods. For the full cash flow conversion analysis, see XRP2 cash flow conversion.
Annual Financial Flexibility Index for SILENCE THERAP. SP.ADR/1 (2021–2025)
Year-by-year free cash flow to debt coverage for SILENCE THERAP. SP.ADR/1. Explore SILENCE THERAP. SP.ADR/1 (XRP2) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.90x | €-62.22 Million | €-62.27 Million | €69.14 Million | ▲ +8.4% |
| 2024 | -0.98x | €-67.43 Million | €-67.64 Million | €68.61 Million | ▼ -93.9% |
| 2023 | -0.51x | €-49.41 Million | €-49.46 Million | €97.45 Million | ▲ +7.2% |
| 2022 | -0.55x | €-56.50 Million | €-57.04 Million | €103.38 Million | ▼ -688.6% |
| 2021 | 0.09x | €10.99 Million | €9.19 Million | €118.32 Million | — |